Literature DB >> 3947867

Haemodynamic effects of intra-arterial and intravenous administration of prostaglandin E1 in patients with peripheral arterial disease.

M Hirai, R Nakayama.   

Abstract

The purpose of this study was to compare the haemodynamic effects of intra-arterial and intravenous prostaglandin E1 (PGE1) both injected and infused into ischaemic legs. Continuous intra-arterial infusion of PGE1 induced a significantly greater increase in skin temperature and blood flow than did intravenous drip infusion. Furthermore, intra-arterial infusion caused no steal phenomenon in the toe as indicated by skin temperature. On the other hand, toe skin temperature decreased during intravenous drip in 33 per cent of the legs tested. Continuous intravenous infusion also produced a significantly greater increase in toe skin temperature than did brief intravenous drip. In three of ten ulcers healed by continuous intra-arterial infusion, no definitive effect was obtained from continuous intravenous infusion even when it was repeated up to three times before continuous intra-arterial infusion. Intra-arterial injection of PGE1 caused no significant increase in toe skin temperature.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3947867     DOI: 10.1002/bjs.1800730109

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  3 in total

1.  Current surgery/drug combination treatment of diabetic gangrene of the foot.

Authors:  E Lange
Journal:  Infection       Date:  1991       Impact factor: 3.553

2.  Development, Optimization, and Characterization of PEGylated Nanoemulsion of Prostaglandin E1 for Long Circulation.

Authors:  Ying Cheng; Miao Liu; Huijing Hu; Daozhou Liu; Siyuan Zhou
Journal:  AAPS PharmSciTech       Date:  2015-07-21       Impact factor: 3.246

3.  Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion.

Authors:  W Cawello; A Leonhardt; H Schweer; H W Seyberth; R Bonn; A L Lomeli
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.